FDA Grants QIDP Designation to VT-1598 for Treatment of Valley Fever

Molecule Adds to Broad Portfolio of Best-In-Class Drug Candidates Discovered by Viamet

Viamet Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to VT-1598, a novel candidate for the oral treatment of coccidioidomycosis, or Valley Fever. Valley Fever is an invasive fungal infection found primarily in the southwest United States that affects an estimated 150,000 people annually.